EUVIMEDEUVIMED entdecken
Crossref

Critical appraisal of total gastrectomy plus total colectomy with hyperthermic intraperitoneal chemotherapy as a treatment for advanced pseudomyxoma peritonei

Paul H Sugarbaker, David Chang

Journal of Surgical Oncology · 2024

DOI: 10.1002/jso.27742 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Paul H Sugarbaker und 1 weiteren Autor:innen. Beteiligte Einrichtung: Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Hyperthermic Intraperitoneal Chemotherapy, Pseudomyxoma Peritonei, Gastrectomy, Colectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Foundation for Applied Research in Gastrointestinal Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The absolute requirement for a long‐term favorable result with cytoreductive surgery for pseudomyxoma peritonei is a complete resection of all visible disease. A combination of parietal peritonectomy procedures and visceral resections is required for this to occur. The cytoreductive surgery is supplemented by hyperthermic intraperitoneal chemotherapy.

Methods

We searched our database and secured files for patients who required a total gastrectomy and a total colectomy to achieve a complete cytoreductive surgery. Survival of low‐grade mucinous neoplasm (LAMN) and mucinous appendiceal adenocarcinoma (MACA) histologies were determined. Clinical and histologic variables were assessed for their impact on survival.

Results

Thirteen of 450 patients (2.9%) with LAMN histology and 14 of 186 patients (7.5%) with MACA histology had these visceral resections. Median survival of these 27 patients was 10 years. LAMN and MACA patients showed the same survival. For LAMN histology, this requirement for extensive visceral resection markedly reduced survival ( p < 0.0001). For MACA, there was no adverse impact on survival ( p = 0.4359). Class 4 adverse events caused reduced survival ( p = 0.0014).

Conclusions

A 10‐year median survival accompanies total gastrectomy plus total colectomy for advanced pseudomyxoma peritonei. Systemic chemotherapy and class 4 adverse events reduced survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperthermic Intraperitoneal ChemotherapyPseudomyxoma PeritoneiGastrectomyColectomyPeritoneal NeoplasmsAppendiceal NeoplasmsAdenocarcinoma, MucinousHumansFemaleMaleMiddle AgedAgedAdultCytoreduction Surgical ProceduresCombined Modality TherapySurvival RateRetrospective StudiesAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

HIPECcytoreductive surgeryileostomyjejunostomymitomycin Cperitonectomy

Autor:innen und Institutionen

  • Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, District of Columbia, USA.
  • Westat, Rockville, Maryland, USA.

Förderung

  • Foundation for Applied Research in Gastrointestinal Oncology

Zitieren

APA

Sugarbaker, P. H., & Chang, D. (2024). Critical appraisal of total gastrectomy plus total colectomy with hyperthermic intraperitoneal chemotherapy as a treatment for advanced pseudomyxoma peritonei. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27742

Vancouver

Sugarbaker PH, Chang D. Critical appraisal of total gastrectomy plus total colectomy with hyperthermic intraperitoneal chemotherapy as a treatment for advanced pseudomyxoma peritonei. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27742

BibTeX
@article{Sugarbaker2024,
  author = {Sugarbaker, Paul H and Chang, David},
  title = {Critical appraisal of total gastrectomy plus total colectomy with hyperthermic intraperitoneal chemotherapy as a treatment for advanced pseudomyxoma peritonei},
  journal = {Journal of Surgical Oncology},
  year = {2024},
  doi = {10.1002/jso.27742}
}
Kostenlos starten →